Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
about
Enzyme replacement therapy for Anderson-Fabry diseaseQuantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis.A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features.Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
P2860
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Changes in plasma and urine gl ...... ver 1 year of agalsidase alfa.
@en
Changes in plasma and urine gl ...... ver 1 year of agalsidase alfa.
@nl
type
label
Changes in plasma and urine gl ...... ver 1 year of agalsidase alfa.
@en
Changes in plasma and urine gl ...... ver 1 year of agalsidase alfa.
@nl
prefLabel
Changes in plasma and urine gl ...... ver 1 year of agalsidase alfa.
@en
Changes in plasma and urine gl ...... ver 1 year of agalsidase alfa.
@nl
P2093
P2860
P356
P6366
P1433
P1476
Changes in plasma and urine gl ...... ver 1 year of agalsidase alfa.
@en
P2093
Atul Mehta
Bruce A Barshop
David Amato
Derek Blankenship
Joe T R Clarke
Markus Ries
Michael Beck
Michael West
Nitin Nair
Pedro Huertas
P2860
P2888
P304
P356
10.1038/GIM.2013.56
P407
P50
P577
2013-05-16T00:00:00Z
P5875
P6179
1007137709
P6366
2056048699